TY - JOUR AU - Giffard-Quillon, Lorine AU - Desmurs-Clavel, Helene AU - Grange, Claire AU - Jourdy, Yohann AU - Dargaud, Yesim PY - 2020 DA - 2020/08/24 TI - Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation? JO - Thrombosis Journal SP - 15 VL - 18 IS - 1 AB - Rivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting the haemostatic balance towards hypercoagulability. We assessed the in vitro efficacy and safety of three 4-factor PCCs for reversing rivaroxaban anticoagulant effect. Our in vitro finding indicates that 4-factor PCCs at the dose of 25 U.kg− 1 may be sufficient to reverse rivaroxaban anticoagulant effect. SN - 1477-9560 UR - https://doi.org/10.1186/s12959-020-00228-9 DO - 10.1186/s12959-020-00228-9 ID - Giffard-Quillon2020 ER -